Omicron Spike
Monoclonal antibodies (mAbs) are directed against the Spike protein and small molecules interfering with the viral replication machinery. Recent cell culture data indicates that the SARS-CoV-2 variant of concern (VOC) Omicron is not susceptible to most of the approved mAbs making it unlikely that their clinical efficacy will be maintained.